At present, there is no molecular marker that could help us to select these patients. The inclusion criteria of the PS3 trial specified at least two bone lesions detected by conventional imaging techniques. So in our present situation with molecular imaging incorporating more and more quickly into clinical practice, it’s difficult to interpret if these patients are the same population as in the study...
At present, there is no molecular marker that could help us to select these patients. The inclusion criteria of the PS3 trial specified at least two bone lesions detected by conventional imaging techniques. So in our present situation with molecular imaging incorporating more and more quickly into clinical practice, it’s difficult to interpret if these patients are the same population as in the study. But in the same way as in localized prostate cancer, we use molecular techniques to decide on treatment. Probably these molecular techniques, PSMA, PET-CT, and so on, could help us to identify patients in an early fashion. So I think this could be the answer for this kind of patient.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
